These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14649078)

  • 1. [Widened indications. More latitude with insulin analogs].
    MMW Fortschr Med; 2003 Sep; 145(39):52. PubMed ID: 14649078
    [No Abstract]   [Full Text] [Related]  

  • 2. Which insulin, when?
    Hauser T; Chisholm DJ
    Aust Fam Physician; 1993 Sep; 22(9):1573-7, 1579-81. PubMed ID: 8240121
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin treatment. When, where and how should insulin be given?].
    Olsson PO
    Vardfacket; 1990 Feb; 14(3):II-VI. PubMed ID: 2188455
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy.
    Shalitin S; Phillip M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S121-4. PubMed ID: 18227471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premixed biphasic insulin analogs - a choice for pediatric patients with type 2 diabetes rather than type 1 diabetes?
    Danne T
    Pediatr Diabetes; 2006 Feb; 7(1):1-3. PubMed ID: 16489967
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting.
    Hahr AJ; Molitch ME
    Am J Ther; 2008; 15(6):543-50. PubMed ID: 19127139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs.
    Rossetti P; Porcellati F; Bolli GB; Fanelli CG
    Diabetes Care; 2008 Feb; 31 Suppl 2():S113-20. PubMed ID: 18227470
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
    Gerich JE
    Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new long-acting insulin analog. "Fewer hypoglycemias observed"].
    Gallwitz B
    MMW Fortschr Med; 2004 Jan; 146(3-4):47. PubMed ID: 15035450
    [No Abstract]   [Full Text] [Related]  

  • 12. [New methods in insulin treatment].
    Neuwirth G
    Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long acting insulin analogs: possibly more stable glucose regulation].
    van der Wal PS; van de Kraats GB
    Ned Tijdschr Geneeskd; 2004 Nov; 148(45):2248. PubMed ID: 15568633
    [No Abstract]   [Full Text] [Related]  

  • 14. [Long-acting insulin analogs: progressing slowly].
    Geelhoed-Duijvestijn PH
    Ned Tijdschr Geneeskd; 2004 Nov; 148(45):2248; author reply 2248-9. PubMed ID: 15568634
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-prandial administration of insulin lispro with a high fat meal minimizes risk of hypoglycaemia in Type 1 diabetes.
    McAulay V; Ferguson SC; Frier BM
    Diabet Med; 2004 Aug; 21(8):953-4. PubMed ID: 15270807
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of insulin analogs.
    Brixner DI; McAdam-Marx C
    Am J Manag Care; 2008 Nov; 14(11):766-75. PubMed ID: 18999911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin antibody formation. I. The influence of age, sex, infections, insulin dosage and regulation of diabetes.
    Andersen OO
    Acta Endocrinol (Copenh); 1972 Sep; 71(1):126-40. PubMed ID: 4678008
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2008 resource guide. Insulin. Along with human insulin analogs, recombinant DNA human insulins are the most widely used insulins in this country. Through genetic engineering, bacteria or yeast are transformed into little "factories" that produce synthetic human insulin.
    Diabetes Forecast; 2008 Jan; 61(1):RG11-4. PubMed ID: 18290288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.